HANGZHOU TIGERMED CO. H 1 (F:5HZ1) — Market Cap & Net Worth
Market Cap & Net Worth: HANGZHOU TIGERMED CO. H 1 (5HZ1)
HANGZHOU TIGERMED CO. H 1 (F:5HZ1) has a market capitalization of $587.30 Million (€502.35 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #11238 globally and #1290 in its home market, demonstrating a -1.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HANGZHOU TIGERMED CO. H 1's stock price €4.08 by its total outstanding shares 123124800 (123.12 Million). See 5HZ1 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
HANGZHOU TIGERMED CO. H 1 Market Cap History: 2021 to 2026
HANGZHOU TIGERMED CO. H 1's market capitalization history from 2021 to 2026. Data shows change from $889.77 Million to $587.30 Million (-14.78% CAGR).
HANGZHOU TIGERMED CO. H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HANGZHOU TIGERMED CO. H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
HANGZHOU TIGERMED CO. H 1's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.74x
HANGZHOU TIGERMED CO. H 1's market cap is 0.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $889.77 Million | $5.21 Billion | $2.87 Billion | 0.17x | 0.31x |
| 2022 | $969.12 Million | $7.09 Billion | $2.01 Billion | 0.14x | 0.48x |
| 2023 | $514.39 Million | $7.38 Billion | $2.02 Billion | 0.07x | 0.25x |
| 2024 | $526.84 Million | $6.60 Billion | $405.14 Million | 0.08x | 1.30x |
| 2025 | $653.51 Million | $6.83 Billion | $887.89 Million | 0.10x | 0.74x |
Competitor Companies of 5HZ1 by Market Capitalization
Companies near HANGZHOU TIGERMED CO. H 1 in the global market cap rankings as of August 4, 2026.
Key companies related to HANGZHOU TIGERMED CO. H 1 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.77 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #169 globally with a market cap of $137.72 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.48 Billion USD ( CN¥317.64 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #616 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.77 Billion | $574.30 |
| #169 | Danaher Corporation | NYSE:DHR | $137.72 Billion | $194.98 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.48 Billion | CN¥128.43 |
| #616 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $559.07 |
HANGZHOU TIGERMED CO. H 1 Historical Marketcap From 2021 to 2026
Between 2021 and today, HANGZHOU TIGERMED CO. H 1's market cap moved from $889.77 Million to $ 587.30 Million, with a yearly change of -14.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €587.30 Million | -10.13% |
| 2025 | €653.51 Million | +24.04% |
| 2024 | €526.84 Million | +2.42% |
| 2023 | €514.39 Million | -46.92% |
| 2022 | €969.12 Million | +8.92% |
| 2021 | €889.77 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of HANGZHOU TIGERMED CO. H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $587.30 Million USD |
| MoneyControl | $587.30 Million USD |
| MarketWatch | $587.30 Million USD |
| marketcap.company | $587.30 Million USD |
| Reuters | $587.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more